PDA Letter Article

Quality and Innovation are Not Incompatible

by Janmeet Anant, MilliporeSigma

Reports from the 2017 PDA/FDA Joint Regulatory Conference

Peter Marks
CBER Director Peter W. Marks discusses his perspective on innovation

Quality is essential no matter how revolutionary the drug product. That concept permeated the 2017 PDA/FDA Joint Regulatory Conference: “Ensuring Product Quality in an Era of Innovative Therapies,” Sept. 11–13, in Washington, D.C.

Three sessions in particular emphasized the spirit behind the theme of the meeting.